Telomir Pharmaceuticals, Inc. (TELO)
| Market Cap | 153.38M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -22.96M |
| Shares Out | 29.61M |
| EPS (ttm) | -0.79 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,313,972 |
| Open | 4.52 |
| Previous Close | 4.54 |
| Day's Range | 4.52 - 5.24 |
| 52-Week Range | 3.11 - 20.72 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 12, 2025 |
About TELO
Telomir Pharmaceuticals, Inc., a preclinical stage pharmaceutical company, is engaged in the advancement of age reversal science. The company is developing Telomir 1, a small molecule intended to lengthen and protect telomeres, the DNA end caps of chromosomes that are associated with cellular aging. Telomir 1 is designed for oral administration and is aimed at extending longevity, improving quality of life, and potentially influencing biological aging. Telomir Pharmaceuticals is also involved in ongoing preclinical research into Progeria, diabe... [Read more]
Financial Performance
Financial StatementsNews
Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price
Transaction follows a $5 million non-dilutive credit line from the same trusted partner, further reinforcing Telomir's financial strength and growth potential. MIAMI, FL / ACCESSWIRE / December 12, 20...
Why Is Telomir Pharmaceuticals Stock Trading Higher On Tuesday?
On Tuesday, Telomir Pharmaceuticals, Inc. TELO revealed preclinical results confirming the efficacy of its licensed molecule Telomir-1 in reversing several key parameters of Type 2 diabetes mellitus.
Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1
MIAMI, FL / ACCESSWIRE / December 3, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), an emerging leader in age-reversal science, today announced groundbreaking preclin...
Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
MIAMI, FL / ACCESSWIRE / November 21, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), an emerging leader in age-reversal science, today announced groundbreaking precli...
Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday
Interview to Air Sunday, September 29, 2024 at 5:30 PM EST on Fox Business Network MIAMI, FL / ACCESSWIRE / September 26, 2024 / Telomir Pharmaceuticals (NASDAQ:TELO) ("Telomir" or the "Company"), a p...
Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications
MIAMI, FL / ACCESSWIRE / September 4, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage company seeking to lead developments in longevity science th...
Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs
Promising results with Telomir-1 Demonstrates Potential in Promoting Life Quality and Longevity in Senior Dogs TAMPA, FL / ACCESSWIRE / August 20, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("...
Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman
Telomir Board of Directors appoints Erez Aminov as CEO and Chairman of the Board Telomir also announces Board of Directors departures and additions TAMPA, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Telom...
Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes
TAMPA, Fla., July 02, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and com...
Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel
Drug Information Association (DIA) 2024 is the largest global, multidisciplinary event for the professionals involved in the discovery, development, and lifecycle management of pharmaceuticals, biotec...
Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1
Commences the study, The Safety of Telomir-1 when Administered Orally to Geriatric Laboratory Beagle Dogs for 63 Consecutive Days study to evaluate the safety of Telomir-1 on geriatric canines
Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.
Telomir-1 elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase that protects the DNA and genetic material in chromosomes to combat aging
Telomir Pharmaceuticals' Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024
Telomir's pre-clinical studies demonstrate its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase
UPDATE – Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines
Study to determine the efficacy of Telomir-1 on mitigating the clinical signs of osteoarthritis and other age-related diseases
Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines
Study to determine the efficacy of Telomir-1 on mitigating the clinical signs of osteoarthritis and other age-related diseases
Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th
Poster presentation delivers pre-clinical results that demonstrate that its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells
Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate's Potential in DNA Age Reversal Science
Continued work with computer-aided pre-clinical testing shows Telomir-1 has the potential to extend DNA telomeres to reverse age-related conditions Continued work with computer-aided pre-clinical test...
Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference
Together with its partner, Frontage Laboratories, Telomir's poster focused on pre-clinical data demonstrating Telomir-1's ability to elongate telomere caps on human stem cells, targeting age-related i...
Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal
Dr. Roizen to provide expertise on longevity and aging Research on aging involving Telomir's lead product candidate focused on reversing age-related decline and the extension of human life BALTIMORE,...
Telomir Pharmaceuticals Announces Closing of Initial Public Offering
BALTIMORE, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and comme...
Telomir Pharmaceuticals Announces Pricing of Initial Public Offering
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company focused on the development and...
IPO Update: Telomir Pharmaceuticals Proposes IPO Terms
Telomir Pharmaceuticals plans to raise $7 million through an IPO to fund its development of treatments for age-related inflammatory conditions. The company's lead candidate, TELOMIR-1, has the potenti...
Small molecule biotech Telomir Pharmaceuticals files for a $14 million IPO
Telomir Pharmaceuticals, a preclinical biotech developing an oral small molecule for age- and cancer-related conditions, filed on Tuesday with the SEC to raise up to $14 million in an initial public o...
Telomir Pharmaceuticals IPO Registration Document (S-1)
Telomir Pharmaceuticals has filed to go public with an IPO on the NASDAQ.